C-Peptide Protein (full length)
This Synthetic C-Peptide protein is expressed in Human.
Quick Overview for C-Peptide Protein (full length) (ABIN934540)
抗原
See all C-Peptide 蛋白
C-Peptide
蛋白类型
Synthetic
宿主
人
资源
Human
纯度
> 98 % pure
-
-
产品特性
- full length
-
序列
- Arg-Arg-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-Lys-Arg
-
产品特性
-
Purified recombinant Human C Peptide protein
Protein Source: Human (full length synthetic C-peptide) Tyr-C-Peptide -
纯化方法
- purified
-
-
-
-
应用备注
- Each Investigator should determine their own optimal working dilution for specific applications.
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
缓冲液
- Supplied as a lyophilized powder purified by HPLC, tyrosine residue.
-
注意事项
- Avoid repeated freeze/thaw cycles.
-
储存条件
- -20 °C
-
储存方法
- Aliquot and store at -20 °C.
-
-
- C-Peptide
-
别名
- C Peptide
-
背景
-
Proinsulin C-peptide was first described in 1967 in connection with the discovery of the insulin biosynthesis. It serves as an important linker between the A- and the B- chains of insulin and facilitates the efficient assembly, folding, and processing of insulin in the endoplasmic reticulum. Equimolar amounts of C-peptide and insulin are then stored in secretory granules of the pancreatic beta cells and both are eventually released to the portal circulation. Initially, the sole interest in C-peptide was as a marker of insulin secretion and has as such been of great value in furthering the understanding of the pathophysiology of type 1 and type 2 diabetes. The first documented use of the C-peptide test was in 1972. During the past decade, however, C-peptide has been found to be a bioactive peptide in its own right, with effects on microvascular blood flow and tissue health.
Description: Human (full length synthetic C-peptide) Tyr-C-Peptide.
Alternative Names: Proinsulin connecting peptide, C-Peptide protein -
分子量
- 3616.99 kDa
抗原
-
You are here:
